Navigation Links
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
Date:11/10/2008

Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at

the ASH Meeting December 6-9, 2008

COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session. Headline interim data from the study was announced in July 2008.

In addition, two abstracts on pre-clinical ofatumumab data have been accepted for presentation at poster sessions. All three ofatumumab abstracts are available on the ASH website at http://www.hematology.org.

ASH Sessions

Oral Presentation December 8 at 11:45AM PST - Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial.

Poster I-682 - Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers.

Poster I-683 - Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site) of the CD20 molecule on t
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Genmab Announces Results for the First Nine Months of 2008
2. Genmab Reaches Milestone in Ofatumumab Collaboration
3. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
4. Genmab A/S - Changes Board/Management/Auditors
5. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
6. Genmab Announces 2008 First Quarter Results
7. Passing of Genmab A/S Annual General Meeting
8. Genmab A/S - Notice to Convene Annual General Meeting
9. Genmabs 2007 Annual Report
10. Genmab Announces Year End 2007 Financial Results
11. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...Newswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVA... the Phase II clinical study of its trivalent seas... vaccine candidate in healthy adults 60 years of a...le-blind, active-controlled study is comparing the...fferent doses (15 mcg and 60 mcg) of Novavax,s tri...
(Date:11/30/2009)...PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ),...cal-device research and,development outsourcing co...es,announced that it had been selected to the Del...ifth consecutive year. The list recognizes the 50,...edia, and telecommunications,industries based on r...
(Date:11/27/2009)... Cromoz Inc., located in Research T...anotube-based cancer drug delivery system in Hyder...hich have functional groups on the walls that allo...d in partnership with the Indian Institute of Kanp...s a drug delivery vehicle with the ability to targ...
(Date:11/25/2009)...swire/ -- Biotech firm Replikins Ltd., which has a... pandemic through the prediction, outbreak, and pr...its latest biochemical analysis of the virus. The ...ine Flu") virus has dropped from its peak of 3.7 (...he spring of 2009 to resting non-epidemic levels t...
Breaking Biology Technology:NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5
...LE, Virginia, April 2 Biovista Inc. today,announc...osis (MS), has shown,significant positive results ...myelitis (EAE) murine model of MS. BVA-101, an exi... aimed at neuroprotection, was shown to,have both ... in this well,established model of MS. , "We a...
... 2 Nuevolution A/S today announced that Merck &am...ase of the collaboration agreement announced in Ju...cs(R) drug discovery technology to identify novel ... , , By entering the second phase, Merck gains ac...rary of small molecule drug candidates. In additi...
..., April 1 On April 1, 2009, Xmark Opportunity Par...ger of Xmark Opportunity Fund, L.P. and Xmark Oppo...he Board of Directors of Icagen, Inc. (Nasdaq: I...UNITY PARTNERS, LLC, ... Suite 201, ...
Other Biology Technology:Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis 2Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc. 2Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign 2
(Date:11/30/2009)...ia, Nov. 30 Neurotechnology ( http...recision biometric identification technologies, ha...product line: VeriLook 4.0 Software Development ... 3.1 SDK for large-scale multi-biometric and autom...panded capabilities in VeriLook 4.0 provide enhanc...
(Date:11/26/2009)...t a way of using recordings of birdsong to accurat...the first time sound recordings from a microphone ... of bird species, populations. Because the new tec...,s Journal of Applied Ecology , will also work wi... our ability to monitor whale and dolphin numbers....
(Date:11/26/2009)...hylococcus Aureus ) and other drug-resistant bacte...sma prototype devices have been developed to offer...tails. , Two prototype devices have been develop... (e.g. hands and feet) in hospitals and public spa...nother to shoot bacteria-killing agents into infes...
Breaking Biology News(10 mins):New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Ecologists sound out new solution for monitoring cryptic species 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 1TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 2TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 3TGen led team is 1 of 7 selected for 241 million skin cancer grants 53469 4IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 1IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 2IDEAL LIFEs Remote Monitoring System Benefits Rural North Carolina Communities 53465 3Yongye International Announces Branded Store Network Increases Over 40 25 to 5 000 Stores 13323 1Yongye International Announces Branded Store Network Increases Over 40 25 to 5 000 Stores 13323 2Yongye International Announces Branded Store Network Increases Over 40 25 to 5 000 Stores 13323 3
... Smithsonian ecologist Kathy Boomer suggests it is...ed management. Boomer has been examining the tools...ediment runs into the Chesapeake Bay, and by her a...uthored by SERC ecological modeler Donald Weller a.../February issue of the Journal of Environmental Qu...
...08) -- The Prostate Cancer Foundation, largely thr... million to four institutions, including Weill Cor... prostate cancer. The gift is one of the largest-e...rch. , The multidisciplinary research team, creat... develop a novel nanomedicine for prostate cancer ...
...dams appear to be threatening the health of Lake V... who depend on the lake for food. A new study sugg... decreased the lake level by at least two meters b...nfluenced by weather. The study by Yustina Kiwango...ames Cook University in Australia was published on...
Other Biology News:Smithsonian study: Sediment prediction tools off the mark 2Nanomedicine research for prostate cancer supported by $5 million gift 2Nanomedicine research for prostate cancer supported by $5 million gift 3New threat to Lake Victoria? 2
Mouse Anti-CKII beta Monoclonal Antibody, Unconjugated from Abcam
...ased selection system for recombinant identificati... survival, eliminating the need for costly color s...des close to 100% accuracy in recombinant selectio... colony picking. This cloning kit is customized a...
Anti-Poly (ADP-Ribose) Polymerase from Roche Applied Science
F40 Pump Maintenance Kit from Bio-Rad
Biology Products: